JP5566106B2 - 歯周病の阻止および治療、歯周創傷の治癒の改善および口腔衛生の促進を目的とする新規薬物 - Google Patents
歯周病の阻止および治療、歯周創傷の治癒の改善および口腔衛生の促進を目的とする新規薬物 Download PDFInfo
- Publication number
- JP5566106B2 JP5566106B2 JP2009526573A JP2009526573A JP5566106B2 JP 5566106 B2 JP5566106 B2 JP 5566106B2 JP 2009526573 A JP2009526573 A JP 2009526573A JP 2009526573 A JP2009526573 A JP 2009526573A JP 5566106 B2 JP5566106 B2 JP 5566106B2
- Authority
- JP
- Japan
- Prior art keywords
- plasminogen
- periodontal disease
- tissue
- periodontal
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000028169 periodontal disease Diseases 0.000 title claims description 88
- 230000003239 periodontal effect Effects 0.000 title description 52
- 208000027418 Wounds and injury Diseases 0.000 title description 44
- 206010052428 Wound Diseases 0.000 title description 40
- 230000035876 healing Effects 0.000 title description 15
- 230000001737 promoting effect Effects 0.000 title description 12
- 239000002547 new drug Substances 0.000 title description 3
- 102000013566 Plasminogen Human genes 0.000 claims description 189
- 108010051456 Plasminogen Proteins 0.000 claims description 189
- 210000001519 tissue Anatomy 0.000 claims description 98
- 208000015181 infectious disease Diseases 0.000 claims description 51
- 238000011282 treatment Methods 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 43
- 230000001580 bacterial effect Effects 0.000 claims description 30
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 230000001338 necrotic effect Effects 0.000 claims description 23
- 230000002458 infectious effect Effects 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 17
- 201000001245 periodontitis Diseases 0.000 claims description 15
- 208000006389 Peri-Implantitis Diseases 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 13
- 208000007565 gingivitis Diseases 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- 230000029774 keratinocyte migration Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000006072 paste Substances 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 5
- 239000000865 liniment Substances 0.000 claims description 5
- 230000007838 tissue remodeling Effects 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 210000004969 inflammatory cell Anatomy 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000606 toothpaste Substances 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 3
- 201000010927 Mucositis Diseases 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 241000021559 Dicerandra Species 0.000 claims 1
- 206010018296 Gingivitis ulcerative Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 121
- 229940012957 plasmin Drugs 0.000 description 67
- 108010088842 Fibrinolysin Proteins 0.000 description 66
- 230000002950 deficient Effects 0.000 description 60
- 238000000034 method Methods 0.000 description 50
- 230000033885 plasminogen activation Effects 0.000 description 38
- 230000037361 pathway Effects 0.000 description 35
- 210000000988 bone and bone Anatomy 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 30
- 238000002347 injection Methods 0.000 description 27
- 239000007924 injection Substances 0.000 description 27
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 26
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 26
- 230000007123 defense Effects 0.000 description 25
- 206010028851 Necrosis Diseases 0.000 description 24
- 230000017074 necrotic cell death Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 239000013543 active substance Substances 0.000 description 21
- 210000000629 knee joint Anatomy 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- 230000029663 wound healing Effects 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 14
- 230000000877 morphologic effect Effects 0.000 description 14
- -1 tPA Proteins 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 208000004575 Infectious Arthritis Diseases 0.000 description 12
- 208000025255 bacterial arthritis Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000007943 implant Substances 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 108010049112 miniplasminogen Proteins 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 108010015052 miniplasmin Proteins 0.000 description 11
- 210000004872 soft tissue Anatomy 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 102000001938 Plasminogen Activators Human genes 0.000 description 10
- 108010001014 Plasminogen Activators Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000001847 jaw Anatomy 0.000 description 10
- 210000000214 mouth Anatomy 0.000 description 10
- 229940127126 plasminogen activator Drugs 0.000 description 10
- 210000003296 saliva Anatomy 0.000 description 10
- 108010023197 Streptokinase Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 108010087750 lysyl-plasminogen Proteins 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 229960005202 streptokinase Drugs 0.000 description 9
- 101710145796 Staphylokinase Proteins 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 108010058207 Anistreplase Proteins 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010039185 Tenecteplase Proteins 0.000 description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 7
- 229960003318 alteplase Drugs 0.000 description 7
- 229960000983 anistreplase Drugs 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 108010075698 monteplase Proteins 0.000 description 7
- 229950005805 monteplase Drugs 0.000 description 7
- 108010085108 pamiteplase Proteins 0.000 description 7
- 229950003603 pamiteplase Drugs 0.000 description 7
- 108010051412 reteplase Proteins 0.000 description 7
- 229960002917 reteplase Drugs 0.000 description 7
- 229960000216 tenecteplase Drugs 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002797 proteolythic effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 239000006142 Luria-Bertani Agar Substances 0.000 description 5
- 208000002847 Surgical Wound Diseases 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000004053 dental implant Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 244000062730 Melissa officinalis Species 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 210000004195 gingiva Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000605986 Fusobacterium nucleatum Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 108010051044 lanoteplase Proteins 0.000 description 3
- 229950010645 lanoteplase Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 241000606750 Actinobacillus Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000589996 Campylobacter rectus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010064687 Device related infection Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000034619 Gingival inflammation Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000024693 gingival disease Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004373 mandible Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 206010063746 Accidental death Diseases 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 229920001605 Dextranomer Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108010029690 procollagenase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940115037 santyl Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82366506P | 2006-08-28 | 2006-08-28 | |
| US60/823,665 | 2006-08-28 | ||
| US94411107P | 2007-06-15 | 2007-06-15 | |
| US60/944,111 | 2007-06-15 | ||
| PCT/SE2007/050586 WO2008027000A2 (en) | 2006-08-28 | 2007-08-28 | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010502601A JP2010502601A (ja) | 2010-01-28 |
| JP2010502601A5 JP2010502601A5 (https=) | 2010-10-21 |
| JP5566106B2 true JP5566106B2 (ja) | 2014-08-06 |
Family
ID=39136398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526573A Expired - Fee Related JP5566106B2 (ja) | 2006-08-28 | 2007-08-28 | 歯周病の阻止および治療、歯周創傷の治癒の改善および口腔衛生の促進を目的とする新規薬物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20100028321A1 (https=) |
| EP (1) | EP2056865B1 (https=) |
| JP (1) | JP5566106B2 (https=) |
| AU (1) | AU2007290882B2 (https=) |
| CA (1) | CA2662083C (https=) |
| DK (1) | DK2056865T3 (https=) |
| ES (1) | ES2453496T3 (https=) |
| WO (1) | WO2008027000A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007290881B2 (en) | 2006-08-28 | 2013-03-07 | Omnio Healer Ab | Candidates against infection |
| US20130164228A1 (en) * | 2011-12-21 | 2013-06-27 | Colgate-Palmolive Company | Compositions comprising gallates and gallamides |
| US9723558B2 (en) | 2012-04-27 | 2017-08-01 | Qualcomm Incorporated | Method and apparatus for signaling in dense network operations |
| CN104721621A (zh) * | 2015-03-24 | 2015-06-24 | 孟勇 | 一种治疗种植体周围炎的药物组合物及其应用 |
| ES2671844B1 (es) | 2015-06-11 | 2019-03-22 | Attwill Medical Solutions Inc | Dispositivos médicos, sistemas y métodos que utilizan composiciones de anti-trombina heparina. |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| HK1259294A1 (zh) * | 2015-11-10 | 2019-11-29 | 耶鲁大学 | 用於治疗自身免疫疾病和癌症的组合物及方法 |
| JP6876066B2 (ja) * | 2015-12-18 | 2021-05-26 | タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 子宮膣部びらんを予防及び治療するための方法 |
| TWI624268B (zh) | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑 |
| WO2018107688A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂肪肝的方法 |
| TWI746581B (zh) * | 2016-12-15 | 2021-11-21 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途 |
| WO2018107707A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
| US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| TWI787732B (zh) * | 2020-02-06 | 2022-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防和治療多發性硬化症的方法和藥物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3023143A (en) | 1959-10-14 | 1962-02-27 | American Cyanamid Co | Process for preparing a veterinary composition |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| US5397578A (en) | 1994-03-29 | 1995-03-14 | Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" | Method of treatment of chronic purulent inflammations of ear in children |
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| AU5390699A (en) * | 1998-07-24 | 2000-02-14 | Pharmacal Biotechnologies, Inc. | Osseous tissue reconstruction system and method |
| AU3862900A (en) * | 1999-03-01 | 2000-09-21 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
| US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| JP4458240B2 (ja) * | 2001-11-26 | 2010-04-28 | ジェネンテック インコーポレイテッド | カテーテル組成物とその用途 |
| AU2003210137A1 (en) | 2002-02-06 | 2003-09-02 | N-Zyme Biotec Gmbh | Method for producing recombinant proteins in micro-organisms |
| CN1420126A (zh) | 2002-07-10 | 2003-05-28 | 牛勃 | 一种重组人纤溶酶原Kringle5突变体蛋白rhPK－5的制备方法 |
| AU2007290881B2 (en) | 2006-08-28 | 2013-03-07 | Omnio Healer Ab | Candidates against infection |
-
2007
- 2007-08-28 US US12/439,516 patent/US20100028321A1/en not_active Abandoned
- 2007-08-28 DK DK07794196.1T patent/DK2056865T3/en active
- 2007-08-28 EP EP07794196.1A patent/EP2056865B1/en not_active Not-in-force
- 2007-08-28 AU AU2007290882A patent/AU2007290882B2/en not_active Ceased
- 2007-08-28 CA CA2662083A patent/CA2662083C/en not_active Expired - Fee Related
- 2007-08-28 ES ES07794196.1T patent/ES2453496T3/es active Active
- 2007-08-28 JP JP2009526573A patent/JP5566106B2/ja not_active Expired - Fee Related
- 2007-08-28 WO PCT/SE2007/050586 patent/WO2008027000A2/en not_active Ceased
-
2015
- 2015-10-23 US US14/921,758 patent/US10086052B2/en active Active
-
2018
- 2018-08-28 US US16/114,940 patent/US20180360931A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008027000A3 (en) | 2008-05-22 |
| US20100028321A1 (en) | 2010-02-04 |
| JP2010502601A (ja) | 2010-01-28 |
| AU2007290882B2 (en) | 2013-02-21 |
| EP2056865B1 (en) | 2013-12-25 |
| US20180360931A1 (en) | 2018-12-20 |
| EP2056865A2 (en) | 2009-05-13 |
| EP2056865A4 (en) | 2012-01-25 |
| AU2007290882A1 (en) | 2008-03-06 |
| ES2453496T3 (es) | 2014-04-08 |
| US10086052B2 (en) | 2018-10-02 |
| US20160184411A1 (en) | 2016-06-30 |
| DK2056865T3 (en) | 2014-03-24 |
| CA2662083A1 (en) | 2008-03-06 |
| CA2662083C (en) | 2016-09-20 |
| WO2008027000A2 (en) | 2008-03-06 |
| HK1134788A1 (en) | 2010-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5566106B2 (ja) | 歯周病の阻止および治療、歯周創傷の治癒の改善および口腔衛生の促進を目的とする新規薬物 | |
| CN101563100B (zh) | 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 | |
| RU2241489C2 (ru) | Композиции матриксных протеинов для залечивания ран | |
| JP5024866B2 (ja) | 創傷治癒のためのマトリックスタンパク質組成物 | |
| EP3500287B1 (en) | Composition comprising self-assembling peptides for use in treatment of periodontitis and/or peri-implantitis | |
| JP2007291115A6 (ja) | 創傷治癒のためのマトリックスタンパク質組成物 | |
| Albonni et al. | Clinical effectiveness of a topical subgingival application of injectable platelet-rich fibrin as adjunctive therapy to scaling and root planing: a double-blind, split-mouth, randomized, prospective, comparative controlled trial. | |
| Pini-Prato et al. | Nonsurgical Treatment of Peri-implantitis Using the Biofilm Decontamination Approach: A Case Report Study. | |
| US10016492B2 (en) | Methods for extracting a tooth | |
| PL219098B1 (pl) | Kompozycja farmaceutyczna do leczenia chorób przyzębia | |
| Jose et al. | Oro-dental regeneration | |
| JP5424353B2 (ja) | 硬組織再生治療用組成物 | |
| HK1134788B (en) | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health | |
| KR20210119453A (ko) | 치주염 치료 및 치간 유두 재생용 조성물 | |
| Goldberg | Prevention for Vulnerable Patients: Atraumatic Carious Treatment and Mild-to-Moderate Periodontal Therapy | |
| RU2440060C1 (ru) | Способ лечения пародонтита | |
| Jensen | The Role of Tristetraprolin in an Experimental Periodontitis Mouse Model | |
| Unit | Nonsurgical Treatment of Peri-implantitis Using the Biofilm Decontamination Approach: A Case Report Study | |
| HK40009191B (en) | Composition comprising self-assembling peptides for use in treatment of periodontitis and/or peri-implantitis | |
| CZ20002986A3 (cs) | Prostředky na bázi proteinů matrice pro hojení ran |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100827 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130806 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131002 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140527 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140617 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5566106 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |